XHKG
1931
Market cap73mUSD
Oct 09, Last price
0.36HKD
1D
0.00%
1Q
-44.62%
IPO
-88.27%
Name
Ivd Medical Holding Ltd
Chart & performance
P/E
14.08
P/S
0.17
EPS
0.02
Div yield, %
34.49%
Shrs. gr., 5y
3.90%
Rev. gr., 5y
3.04%
Revenues
2.82b
-10.81%
Net income
35m
-86.59%
CFO
-919m
L
Dividend
Jul 15, 20240.06209 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ETHK Labs Inc., formerly IVD Medical Holding Ltd, is an investment holding company that distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, After-sales Services, and Self-branded Products Business. It offers a range of products including IVD analyzers, reagents, and consumables.
Key people
Kim Fai Law
Chief Financial Officer, Executive Director, Joint Company Secretary · since 2024
Xianya Lin
General Manager, Executive Director · since 2019
Bo Yang
Financial Controller · since 2019
Siu Kei Chan
Executive Director · since 2024
Yang Tai
Executive Director · since 2025
Zuhou Li
Vice General Manager of Dacheng · since 2012
Fai Pun
General Manager of IVD China Limited · since 2016
Fei Liu
Non-Executive Director · since 2024
Haiyun Yao
Non-Executive Director · since 2021
Da Xu
Non-Executive Independent Director · since 2025
Jianlei Zhang
Non-Executive Independent Director · since 2025
Renqian Zhong
Non-Executive Independent Director · since 2019
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||